Q-omics provides the consensus-scored RAD23B profile across patient tissues and cancer cell-line models. RAD23B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RAD23B is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, RAD23B RNA expression shows 19,665 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where RAD23B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAD23B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAD23B survival associations across molecular data types. RAD23B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAD23B RNA expression–survival associations across cancer types. High RAD23B expression shows unfavorable associations in ACC, HNSC, LUAD and BLCA, but favorable associations in SCLC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RAD23B RNA expression.
This table summarizes RAD23B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RAD23B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAD23B shows higher tumor expression in HNSC, THCA, COAD, BLCA, LUAD and BRCA. The HNSC box plot shows higher RAD23B RNA expression in tumor versus normal tissue (log2 FC = +0.776, t-test p < 0.001).
This table shows molecular features associated with RAD23B in patient tissues and cancer cell lines. In patient samples, RAD23B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAD23B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
